Scientifically reviewed by Dr Stephan Hansberg
Are peptides legal in the US? (2026 FDA status)
Where BPC-157, TB-500, GHK-Cu, KPV and NAD+ stand with the FDA in 2026: the 503A compounding categories, the July 2026 advisory committee vote, research use only sales and what is still pending.
Key takeaways
- •No peptide discussed on this site is an FDA-approved drug for the uses it is popularly discussed for, and none may lawfully be sold as a drug for human use without approval.
- •In April 2026 the FDA removed BPC-157 and a group of other peptides from Category 2 of its 503A bulk substances list, the category for substances raising significant safety concerns.
- •On 23-24 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax to the 503A bulks list. The vote is non-binding and rulemaking was still pending as of October 2026.
- •Research use only sales sit outside the drug approval system, but the FDA has issued warning letters where a seller's website showed the product was really intended for people.
- •This guide is general information as of October 2026, not legal advice. Check the FDA's current 503A lists before relying on any of it.
The short answer
In the United States, research peptides are not scheduled controlled substances, and buying a compound as a laboratory reagent is not in itself a federal crime. What the Federal Food, Drug, and Cosmetic Act regulates is a product intended for use in people: a substance marketed or supplied to diagnose, treat or prevent disease, or to affect the structure or function of the body, is a drug, and a drug needs FDA approval before it can be sold for that use.
So in the US, as in the UK, the legal question turns on intended use. The same molecule can be a lawful research reagent in one context and an unapproved new drug in another, depending on how it is labelled, described and sold.
Compounding and the 503A categories
Licensed US pharmacies can compound medicines for individual patients under section 503A of the Act, but only from bulk substances that qualify. The FDA sorts nominated substances into categories: Category 1 substances may be compounded while they are evaluated, and Category 2 substances are those the FDA considers to raise significant safety risks, which pharmacies should not compound.
BPC-157 was placed in Category 2 in 2023. In April 2026 the FDA removed BPC-157 and a group of other peptides from Category 2. Removal from Category 2 is not the same as approval: it did not move these peptides into Category 1 or onto the bulks list, so it did not by itself make them eligible for routine compounding.
The July 2026 advisory committee vote
On 23-24 July 2026 the FDA's Pharmacy Compounding Advisory Committee met to consider several peptides. By a reported 8-6 vote with one abstention it recommended adding BPC-157 to the 503A bulks list, and it also recommended KPV, TB-500, MOTS-c, Epitalon and Semax, while voting against emideltide. Coverage noted that the committee voted against the FDA staff's written recommendations on several of these substances.
Advisory committee votes are recommendations. The FDA still has to decide and complete rulemaking before any of these peptides joins the bulks list, and as of October 2026 that process had not concluded. Headlines saying the FDA has "cleared" or "legalised" BPC-157 overstate where things stand.
| Compound | FDA-approved drug? | 503A status (Oct 2026) |
|---|---|---|
| BPC-157 | No | Out of Category 2 (Apr 2026); bulks list recommended by PCAC (Jul 2026), rulemaking pending |
| TB-500 | No | Bulks list recommended by PCAC (Jul 2026), rulemaking pending |
| KPV | No | Bulks list recommended by PCAC (Jul 2026), rulemaking pending |
| GHK-Cu | No (topical cosmetic use is separate) | Not among the July 2026 recommendations |
| NAD+ | No approved injectable NAD+ drug | Used in compounding; check current FDA lists |
Research use only sales and FDA warning letters
Suppliers that sell peptides as research chemicals rely on the product being a laboratory reagent rather than a drug. The FDA looks past the label at the whole presentation. Through 2025 and 2026 it sent warning letters to online sellers, particularly of retatrutide and other GLP-1 compounds, saying that research use only statements did not change the fact that the website showed the products were intended for people.
The practical lesson for anyone reading supplier sites: consistency matters. A research supplier whose pages carry dosing charts, protocols or health promises is presenting a drug, whatever the disclaimer says.
Importing into the US
Shipments entering the US can be examined by Customs and Border Protection and the FDA. Products that appear to be unapproved drugs can be detained or refused entry. Rules for personal importation are narrow and discretionary, so it is worth reading current FDA import guidance before ordering from any overseas supplier.
Sources
Primary and secondary sources used for this guide, checked October 2026:
- FDA: Pharmacy Compounding Advisory Committee, 23-24 July 2026 meeting materials (fda.gov)
- FDA: Bulk drug substances nominated for use in compounding under section 503A (fda.gov)
- FDA warning letter to Gram Peptides, 31 March 2026 (fda.gov)
- ABC News: FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list, July 2026
- NCPA: FDA advisory committee nominates six peptides for pharmacies to compound, 31 July 2026
Research use only
Celyfe sells research peptides for laboratory and research use only. This guide is general background information and is not legal advice; the regulatory position in the US is moving, so check current FDA publications or consult a qualified adviser before relying on it.
Regulation alerts
Get notified when the rules change
We email when FDA, MHRA, TGA or WADA status changes for the compounds we cover, with the source linked. No spam, unsubscribe at any time.